MyLungCancerTeam

Liquid biopsies like Signatera ctDNA tests are becoming increasingly common in NSCLC treatment monitoring. While they are useful tools, it's important to understand that they complement rather than replace traditional diagnostic methods. These tests can help doctors predict which targeted therapy treatments might work best Show Full Answer

Liquid biopsies like Signatera ctDNA tests are becoming increasingly common in NSCLC treatment monitoring. While they are useful tools, it's important to understand that they complement rather than replace traditional diagnostic methods. These tests can help doctors predict which targeted therapy treatments might work best for individual patients. For Stage 2 NSCLC patients like yourself, monitoring is particularly important since the tumor characteristics can vary significantly. Your doctors are likely using this less invasive testing approach to track any potential cancer activity while avoiding more invasive procedures like bronchoscopy. The test results, combined with your imaging scans, will help guide your ongoing treatment decisions with Keytruda (immunotherapy).

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

NSCLC: Advances in Diagnosis, Staging, and Metastatic Therapies (VIDEO)

Stages of Lung Cancer: TNM Staging, Limited, Extensive, and More